Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Date:6/12/2008

inancial resources will allow us to continue to execute on our strategy to acquire rights to patented, development stage drug candidates, advance the candidates through proof-of-principle clinical trials and generate value through partnering or our own commercial efforts."

Total revenue for the fourth quarter of fiscal year 2008 was $3,301,000 compared to $3,699,000 for the same period in fiscal year 2007, a decrease of 11%. Operating expenses for the fourth quarter of fiscal year 2008 were $7,165,000 compared to $4,050,000. Net loss for the fourth quarter of fiscal year 2008 was $3,198,000 or $0.10 per diluted share, compared to a net loss for the fourth quarter of fiscal year 2007 of $107,000 or $0.00 per diluted share.

Corporate Update

Secretin (RG1068) for Imaging of the Pancreas

In March, we initiated a Phase 3 clinical trial to evaluate the use of RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). The Phase 3 study is a multi-center, baseline-controlled, single dose study in which approximately 250 patients will receive an unenhanced MRI followed by a secretin-enhanced MRI of the pancreas. The study is designed to assess the sensitivity and specificity of secretin-enhanced MRI to improve the ability to detect pancreatic duct abnormalities relative to MRI alone. Detailed visual assessment of the pancreatic ducts is important in the assessment, diagnosis and treatment of diseases such as acute and chronic pancreatitis. The study is being conducted at approximately 30 clinical sites within the United States and Canada. In April, the U.S. Food and Drug Administration granted Fast Track Designation to our development program. Fast Track is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need.

Uridine (RG2417) for Bipolar Disorder

Today, we announced that based on
'/>"/>

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
2. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
3. Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter
4. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
5. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. Cord Blood America Reports CorCell, Its Major Acquisition in 2006, Turns Profitable
8. Bioheart, Inc. Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
9. Rosetta Genomics Reports First Quarter 2008 Financial Results
10. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
11. Advance Nanotech Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Palm Beach County, Florida (PRWEB) August 27, 2014 ... & Company Inc. (SCI) is announcing the creation ... board’s priority is to take the SCI’s philosophy ... insuring the company’s research and development actions are ... interpretations. , This new Scientific Advisory Board provides ...
(Date:8/27/2014)... City, OR (PRWEB) August 27, 2014 ... Report, “Consolidation continues to reshape the look and feel ... nutrition. Consumer demand for higher-quality ingredients will push for ... North American market have experienced strong market growth in ... ethical attributes in their food and cosmetics to fit ...
(Date:8/27/2014)... Hunting Valley, Ohio (PRWEB) August 27, 2014 ... five students from Cleveland's University School ... at Case Western Reserve University’s School of ... program provides students with an unparalleled professional experience ... with the School of Medicine faculty and students ...
(Date:8/26/2014)... WA (PRWEB) August 26, 2014 ... for next-generation wearable technology, and inspiration for the ... at this year’s brighter, busier SPIE Optics ... Convention Center. More than 4,400 international scientists, engineers, ... courses, an exhibition, and industry sessions sponsored by ...
Breaking Biology Technology:New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 2Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 3Brighter, Busier SPIE Optics + Photonics Draws International Crowd to San Diego 4
... against deadly bacteria. However, how the step from gene to ... To date, B. Pseudomallei, a bacterium suitable for ... in the human body for many years without being detected ... and spread throughout the body, resulting in the patient dying ...
... Apparao Rao and his team are researching nano-scale cantilevers that ... chemicals or gases in the air. Put them into a ... chemical alerts in battle, in industry, in health care and ... devices to do this work has been something we,ve only ...
... 23, 2008 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) ... Medicine that supports the broad anti-viral potential ... showing that its PS-targeting drug bavituximab can cure ... , Bavituximab is in clinical trials for ...
Cached Biology Technology:Clemson researchers advance nanoscale electromechanical sensors 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3
(Date:8/27/2014)... Warwick research finds , Gamblers show the same ... research has shown. , Researchers, led by Dr Elliot ... conducted tests that found that both human gamblers and ... than low-value rewards. , Published in Biology Letters ... the important role that memories of previous biggest wins ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
(Date:8/26/2014)... years, increasing pressure from policymakers, consumers, and suppliers ... go beyond reducing the pollutants they emit from ... Today companies must also assess environmental performance at ... of primary materials to the use and recycling ... rise to the discipline known as life cycle ...
Breaking Biology News(10 mins):Gamblers are greedy bird-brains, University of Warwick research finds 2Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3Yale journal explores advances in sustainable manufacturing 2
... dams already in question, scientists are reporting that millions ... an important contribution to the greenhouse gases linked to ... than previously believed bubbles out of the water behind ... & Technology . Andreas Maeck and colleagues point ...
... Mice and rats have long since been a standard animal ... of four years on average and high incidence of cancer. ... social tiny African subterranean rodent has a maximum lifespan exceeding ... so far, not a single incident of cancer has been ...
... Inc. released today a white paper detailing BioNimbus, a new ... of a package while it is moving through a 3D ... parts of something a person is viewing, and measure biological ... science of optical, neural and biometric measurement. "We ...
Cached Biology News:The naked mole-rat's secret to staying cancer free 2If you see a puppy on a package, are you more likely to buy it? 2
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood CD14+ Monocytes, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Monocytes, B Cells and NK Cells...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Human peripheral blood neutrophils, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Granulocytes...
Biology Products: